 |
 |
|
 | |
| Volume 37, 1 July 2006 | 7/2006 |
| SPOT ON | |
 |
Prevention of type 2 diabetes mellitus: what do results of studies really mean? |
| NEW ON THE MARKET | |
Dopamine-agonists pramipexole (SIFROL) and ropinirole (ADARTEL) for restless legs syndrome | |
| REVIEW | |
Immunotherapy of allergic diseases (II) | |
| THERAPY FROM A CRITICAL VIEWPOINT | |
Once again: Do long-acting beta-2 agonists increase complications of asthma? | |
| a-t READERS' QUESTIONS AND COMMENTS | |
Statins for diabetic patients with end-stage renal disease? | |
| IN BRIEF | |
Oral anticoagulants still first line antithrombotics in chronic atrial fibrillation | |
| CURRENT ADR NETWORK REPORT | |
Suicidality due to levofloxacin (TAVANIC) and other fluoroquinolones | |
| SIDE EFFECTS | |
Infliximab (REMICADE): hepatosplenic gammadelta T-cell lymphoma | |
|
© arznei-telegramm7/2006 | ||
 |  | |